• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Journey Medical Corporation

    11/29/24 2:00:25 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DERM alert in real time by email
    SC 13G 1 p1124243sc13g.htm

     

     

    Securities and Exchange Commission

    Washington, DC 20549

     

    SCHEDULE 13G

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    Journey Medical Corporation

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    48115J109

    (CUSIP Number)

     

    November 21, 2024

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

     

     

     Page 1 of 10 pages 
     

     

    CUSIP No.  48115J109 13G Page 2 of 10 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Management, LLC 

    2 Check the Appropriate Box if a Member of a Group* (a) ¨
    (b)
    ¨
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    DELAWARE 

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    1,523,938

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

        8

    Shared Dispositive Power

     

    1,523,938 

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    1,523,938 

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    7.3% 

    12

    type of reporting person

     

    OO 

     

     Page 2 of 10 pages 
     

     

    CUSIP No.  48115J109 13G Page 3 of 10 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Kevin Tang 

    2 Check the Appropriate Box if a Member of a Group* (a) ¨
    (b)
    ¨
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    united states 

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    1,523,938

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

        8

    Shared Dispositive Power

     

    1,523,938 

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    1,523,938 

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    7.3% 

    12

    type of reporting person

     

    IN 

     

     Page 3 of 10 pages 
     

     

    CUSIP No.  48115J109 13G Page 4 of 10 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP 

    2 Check the Appropriate Box if a Member of a Group* (a) ¨
    (b)
    ¨
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    DELAWARE 

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    1,523,938

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

        8

    Shared Dispositive Power

     

    1,523,938 

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    1,523,938 

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    7.3% 

    12

    type of reporting person

     

    PN 

     

     Page 4 of 10 pages 
     

     

    CUSIP No.  48115J109 13G Page 5 of 10 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS III, INC 

    2 Check the Appropriate Box if a Member of a Group* (a) ¨
    (b)
    ¨
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    NEVADA 

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    0

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

        8

    Shared Dispositive Power

     

    0 

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0 

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0% 

    12

    type of reporting person

     

    CO 

     

     Page 5 of 10 pages 
     

     

    CUSIP No.  48115J109 13G Page 6 of 10 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS IV, INC 

    2 Check the Appropriate Box if a Member of a Group* (a) ¨
    (b)
    ¨
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    NEVADA 

     

    Number of

    5

    Sole Voting Power

     

    0 

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    0

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0 

        8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0% 

    12

    type of reporting person

     

    CO 

     

     Page 6 of 10 pages 
     

     

    Item 1(a).Name of Issuer:

     

    Journey Medical Corporation, a Delaware corporation (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    9237 E Via de Ventura Blvd., Suite 105, Scottsdale, AZ 85258

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Management, LLC, the general partner of Tang Capital Partners, LP (“Tang Capital Management”); Kevin Tang, the manager of Tang Capital Management and Chief Executive Officer of Tang Capital Partners III, Inc. and Tang Capital Partners IV, Inc.; Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Partners III, Inc. (“Tang Capital Partners III”); and Tang Capital Partners IV, Inc. (“Tang Capital Partners IV”).

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    The address of Tang Capital Management, Kevin Tang and Tang Capital Partners is 4747 Executive Drive, Suite 210, San Diego, CA 92121. The address of Tang Capital Partners III and Tang Capital Partners IV is 5955 Edmond Street, Las Vegas, NV 89118.

     

    Item 2(c).Citizenship:

     

    Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen. Tang Capital Partners is a Delaware limited partnership. Tang Capital Partners III and Tang Capital Partners IV are Nevada corporations that are indirectly wholly owned by Tang Capital Partners.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.0001 per share (the “Common Stock”)

     

    Item 2(e).CUSIP Number 48115J109

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)Amount Beneficially Owned:

     

    Tang Capital Management. Tang Capital Management beneficially owns 1,523,938 shares of the Issuer’s Common Stock.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 1,523,938 shares of the Issuer’s Common Stock.

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

     

     Page 7 of 10 pages 
     

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 1,523,938 shares of the Issuer’s Common Stock.

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    The percentages used herein are based on 20,889,936 shares of Common Stock outstanding which consists of 14,889,936 shares of Common Stock and 6,000,000 shares of Class A Common Stock outstanding as of November 11, 2024, as set forth in the Issuer’s Quarterly Report filed on Form 10-Q that was filed with the Securities and Exchange Commission on November 12, 2024.

     

    (b)Percent of Class:

     

    Tang Capital Management 7.3%
    Kevin Tang 7.3%
    Tang Capital Partners 7.3%
    Tang Capital Partners III 0.0%
    Tang Capital Partners IV 0.0%

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote:

     

    Tang Capital Management 0 shares
    Kevin Tang 0 shares
    Tang Capital Partners 0 shares
    Tang Capital Partners III 0 shares
    Tang Capital Partners IV 0 shares

     

    (ii)shared power to vote or to direct the vote:

     

    Tang Capital Management 1,523,938 shares
    Kevin Tang 1,523,938 shares
    Tang Capital Partners 1,523,938 shares
    Tang Capital Partners III 0 shares
    Tang Capital Partners IV 0 shares

     

    (iii)sole power to dispose or to direct the disposition of:

     

    Tang Capital Management 0 shares
    Kevin Tang 0 shares
    Tang Capital Partners 0 shares
    Tang Capital Partners III 0 shares
    Tang Capital Partners IV 0 shares

     

    (iv)shared power to dispose or to direct the disposition of:

     

    Tang Capital Management 1,523,938 shares
    Kevin Tang 1,523,938 shares
    Tang Capital Partners 1,523,938 shares
    Tang Capital Partners III 0 shares
    Tang Capital Partners IV 0 shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

     Page 8 of 10 pages 
     

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 9 of 10 pages 
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: November 29, 2024  
         
    TANG CAPITAL PARTNERS, LP  
         
    By:  Tang Capital Management, LLC, its General Partner  
         
    By: /s/ Kevin Tang  
      Kevin Tang, Manager  
         
    TANG CAPITAL PARTNERS III, INC  
         
    By: /s/ Kevin Tang  
      Kevin Tang, Chief Executive Officer  
         
    TANG CAPITAL PARTNERS IV, INC  
         
    By: /s/ Kevin Tang  
      Kevin Tang, Chief Executive Officer  
         
    TANG CAPITAL MANAGEMENT, LLC  
         
    By: /s/ Kevin Tang  
      Kevin Tang, Manager  
         
    /s/ Kevin Tang  
    Kevin Tang  

      

     

    Page 10 of 10 pages

     

     

     

    Get the next $DERM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DERM

    DatePrice TargetRatingAnalyst
    7/30/2025$12.00Buy
    B. Riley Securities
    8/22/2024$9.00Buy
    Rodman & Renshaw
    6/28/2024$11.00Buy
    ROTH MKM
    2/25/2022$9.00Overweight
    Cantor Fitzgerald
    12/16/2021$15.00Buy
    Roth Capital
    12/7/2021$14.00Buy
    B. Riley Securities
    More analyst ratings

    $DERM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Rosenwald Lindsay A Md bought $30,400 worth of shares (10,000 units at $3.04), increasing direct ownership by 7% to 144,245 units (SEC Form 4)

    4 - Journey Medical Corp (0001867066) (Issuer)

    3/27/24 7:00:16 AM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maraoui Claude bought $34,790 worth of shares (10,000 units at $3.48), increasing direct ownership by 0.46% to 2,163,430 units (SEC Form 4)

    4 - Journey Medical Corp (0001867066) (Issuer)

    3/25/24 4:03:29 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Smith Justin Adam bought $104,100 worth of shares (30,000 units at $3.47), increasing direct ownership by 29% to 134,717 units (SEC Form 4)

    4 - Journey Medical Corp (0001867066) (Issuer)

    3/25/24 4:02:02 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DERM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities resumed coverage on Journey Medical with a new price target

    B. Riley Securities resumed coverage of Journey Medical with a rating of Buy and set a new price target of $12.00

    7/30/25 8:21:38 AM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Journey Medical with a new price target

    Rodman & Renshaw initiated coverage of Journey Medical with a rating of Buy and set a new price target of $9.00

    8/22/24 7:21:37 AM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH MKM resumed coverage on Journey Medical with a new price target

    ROTH MKM resumed coverage of Journey Medical with a rating of Buy and set a new price target of $11.00

    6/28/24 7:38:15 AM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DERM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream

    MIAMI, Aug. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter. Day 1August 20, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go back to the reg

    8/19/25 7:00:00 AM ET
    $ADVM
    $CLNN
    $DERM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Diversified Commercial Services

    Journey Medical Corporation to Present at the Emerging Growth Conference

    SCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will present a corporate overview at the Emerging Growth Conference on Wednesday, August 20, 2025 at 12:35 p.m. ET. All sessions will be conducted virtually through video webcasts. For more information or to register for the conference, please visit: https://emerginggrowth.co

    8/18/25 8:30:18 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

    Second quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June 2025 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results an

    8/12/25 4:01:21 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DERM
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Journey Medical Corporation

    SCHEDULE 13G/A - Journey Medical Corp (0001867066) (Subject)

    8/14/25 1:21:12 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Journey Medical Corporation

    10-Q - Journey Medical Corp (0001867066) (Filer)

    8/12/25 4:36:12 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Journey Medical Corp (0001867066) (Filer)

    8/12/25 4:05:41 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DERM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Rosenwald Lindsay A Md was granted 50,000 shares, increasing direct ownership by 31% to 211,146 units (SEC Form 4)

    4 - Journey Medical Corp (0001867066) (Issuer)

    8/7/25 5:18:06 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Smith Justin Adam was granted 20,000 shares, increasing direct ownership by 13% to 171,618 units (SEC Form 4)

    4 - Journey Medical Corp (0001867066) (Issuer)

    8/7/25 5:17:19 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Toledano Miranda Jayne was granted 20,000 shares, increasing direct ownership by 23% to 108,618 units (SEC Form 4)

    4 - Journey Medical Corp (0001867066) (Issuer)

    8/7/25 5:16:13 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DERM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Journey Medical Corporation

    SC 13G - Journey Medical Corp (0001867066) (Subject)

    11/29/24 2:00:25 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Journey Medical Corporation (Amendment)

    SC 13G/A - Journey Medical Corp (0001867066) (Subject)

    12/29/22 5:15:07 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Journey Medical Corporation

    SC 13G - Journey Medical Corp (0001867066) (Subject)

    8/17/22 4:01:13 PM ET
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DERM
    Financials

    Live finance-specific insights

    View All

    Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

    Second quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June 2025 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results an

    8/12/25 4:01:21 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation to Announce Second Quarter 2025 Financial Results on August 12, 2025

    SCOTTSDALE, Ariz., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2025 financial results after the U.S. financial markets close on Tuesday, August 12, 2025. Journey Medical management will conduct a conference call and audio webcast on Tuesday, August 12, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.

    8/5/25 4:01:19 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

    Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions Filled in Late March 2025 Phase 3 Clinical Trial Results for Emrosi Published in JAMA Dermatology Emrosi Now Included in Updated National Rosacea Society Treatment Algorithms Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz., May 14, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Admin

    5/14/25 4:01:35 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DERM
    Leadership Updates

    Live Leadership Updates

    View All

    Journey Medical to Join Russell 2000® and Russell 3000® Indexes

    SCOTTSDALE, Ariz., June 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as a result of their 2025 annual Russell Index reconstitution. "We are very pleased to be included in the Russell 2000® and Russell 3000

    6/24/25 8:30:29 AM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

    SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer ("COO"). Mr. Alloush will continue to also serve as the Company's General Counsel. Claude Maraoui, President and Chief Executive Officer of Journey Medical, commented, "Ramsey's promotion to COO reflects

    4/1/25 4:01:16 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

    SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that on July 9, 2024, it appointed Michael C. Pearce to its Board of Directors. Mr. Pearce is a principal investor with an emphasis on healthcare. Since 2015, he has served as an advisor to EP Group and board member of its predecessor parent company, Evening Post Industries ("EPI"). At EPI, he served on the audit, compensation, and inves

    7/11/24 4:05:39 PM ET
    $DERM
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care